A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC

Inclusion Criteria: * Age \>18 years * Karnofsky index \>70% * Child-Turgotte-Pugh A or B liver score. * An initial diagnosis of primary HCC or recurrence. * A technically unresectable lesion or medically contraindicated surgery or a case in which surgery was declined. * HCC (single nodule ≤ 5 cm or max 3 nodules ≤ 3 cm) diagnosed by histology or non-invasive EASL criteria * Baseline CT or MRI and bone scan without evidence of radiologically definable major vascular invasion or extrahepatic disease * Hb \>10.5.0 g/%, WBC \>3.000 cells/mm3, platelets \>50.000 cells/mm3, bilirubin \<2 mg/dl, aspartate and alanine aminotransferase levels \<5 times upper normal limit, and prothrombin time-international normalized ratio ≤ 2; * Serum creatinine \<1.7 mg/dl * Previously incomplete TAE or TACE with radiologically defined residual disease. * Informed consent Exclusion Criteria: * Extrahepatic disease and refractory ascites. * Previous abdominal radiation therapy (RT) * Hemorrhage/bleeding event = Grade 3 within 4 weeks of enrollment in the study. * Pregnant or breastfeeding patients. * Patients with uncontrolled infections or HIV seropositive patients. * Mental conditions rendering the patient incapable to understand the nature, scope, and consequences of the study.